Each 1-hour session will include 3 topic modules focused on the current management of, emerging research with and novel agents and strategies under active investigation for non-small cell lung cancer (NSCLC). Each event will employ an identical format that will include the following elements:

• Discussion of Steering Committee Members’ Treatment Recommendations
• Review of Available Clinical Research Findings
• Integration of Interactive Audience Polling Results

Each session will conclude with a 5-minute Q&A segment

STEERING COMMITTEE MEMBERS

Target Audience:
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives:

• Appraise the recent FDA approval of durvalumab consolidation for patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this agent can be appropriately and safely integrated into routine clinical practice.
• Recall the results from the recently presented Phase III FLAURA trial evaluating the role of osimertinib versus gefitinib or erlotinib as first-line therapy for patients with NSCLC with an EGFR mutation, and consider how these findings may affect current or future clinical practice.
• Develop an optimal management approach for patients with NSCLC with an EGFR mutation and CNS metastases, considering the implications of symptomatology, number of lesions and other relevant factors.
• Review published research data documenting the safety and efficacy of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for newly diagnosed metastatic NSCLC, and identify patients appropriate for this strategy outside of a research setting.
• Appreciate the biologic rationale for targeting multiple immune checkpoints simultaneously, and consider the applicability of emerging data documenting the benefit of combined anti-CTLA-4 and anti-PD-1/PD-L1 inhibition in patients with NSCLC and a high tumor mutational burden.
• Recognize immune-related adverse events and other common side effects associated with approved and developmental immune checkpoint inhibitors, and offer supportive management strategies to minimize and manage these toxicities.
• Describe ongoing trials evaluating novel applications of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, novel immune checkpoint inhibitors, targeted therapy) for diverse lung cancer variants, and counsel appropriately selected patients about participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support:
These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.